Germany - Antineoplastic agents

For more information and to make a bid you will need to go to the third party website.

Details

Provided by Open Opps
Opportunity closing date
27 October 2021
Opportunity publication date
18 November 2019
Category
33652100: Antineoplastic agents
Value of contract
to be confirmed
Your guide to exporting
Report opportunity

Description

For the active substance Dasatinib (ATC code: L01XE06) limited to the patent-free indication, AOK - Die Gesundheitskasse für Niedersachsen offers discount contracts to all interested pharmaceutical companies for the period up to the entry into force of exclusive contracts as a result of a formal award procedure in accordance with the regulations of Part 4 of the ARC, without a selection decision. This agreement is subject to approval for the following patent-free indication:a) Treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL) with resistance or intolerance to prior therapy.The AOK - Die Gesundheitskasse für Niedersachsen will inform all relevant physicians about the indication restriction on which the contract is based. The contracts are concluded within the framework of an "open-house model" and are not exclusive; contracts with all market participants (pharmaceutical companies) are desired by the AOK Niedersachsen. In the open-house model, uniform conditions apply to all participants. Contract contents, conditions and access procedures are uniform - individual negotiations are generally not conducted. The contract periods are a maximum of twenty-four months, the earliest commencement date being 1.1.2020. All contracts expire on 31.12.2021 at the latest, irrespective of the date on which the contract was concluded. An accession or a contract conclusion can take place within the twenty-four month period in each case to the first of a month. There is a right of termination 6 weeks to the end of each month. The AOK - Die Gesundheitskasse für Niedersachsen reserves the right to replace the non-exclusive open-house discount contracts with exclusive discount contracts during the term of the contract. When exclusive discount contracts put out to tender come into force, the open-house contracts are terminated in accordance with the contractual provisions, i.e. the open-house contracts end automatically. According to AOK Niedersachsen's experience, exclusive discount agreements generally come into force 6 to 8 months after publication of the corresponding tender notice in the Supplement to the Official Journal of the European Union. Interested pharmaceutical companies can request the contract documents as well as the contractual conditions at the contact address given under I.1).Contracts for the active substance Dasatinib (ATC code: L01XE06) limited to the patent-free indication will be concluded for the first time with effect from 1 January 2020. Interested parties who wish to become contractual partners on this date must submit the contract documents to be submitted to the address stated in the contract documents by 30.11.2019. It depends on the access to the AOK Niedersachsen. Contracts may be concluded at a later date during the maximum twenty-four-month period, beginning on the first day of each month. In terms of organisation, the AOK usually needs a preliminary run of 35 calendar days in order to be able to guarantee the necessary work, e.g. the notification of the contract in the Lauer-Taxe®. The exact deadlines for receipt will be announced together with the contract documents. Since the description of the procurement cannot be completely listed under this item due to a lack of input (lack of space), the "description of the procurement" is continued under "VI.3) Additional information".

Opportunity closing date
27 October 2021
Value of contract
to be confirmed

About the buyer

Address
AOK – Die Gesundheitskasse für Niedersachsen Hildesheimer Str. 273 Hannover 30519 Germany
Contact
rabattvertraege@nds.aok.de

The deadline to apply for this opportunity has passed.
Visit the opportunities page to find another.

Is there anything wrong with this page?